loading
Biolife Solutions Inc stock is currently priced at $17.53, with a 24-hour trading volume of 392.30K. It has seen a +3.97% increased in the last 24 hours and a -3.15% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $16.69 pivot point. If it approaches the $17.71 resistance level, significant changes may occur.
Previous Close:
$16.86
Open:
$16.95
24h Volume:
392.30K
Market Cap:
$794.11M
Revenue:
$143.27M
Net Income/Loss:
$-66.43M
P/E Ratio:
-9.0829
EPS:
-1.93
Net Cash Flow:
$-18.88M
1W Performance:
+10.53%
1M Performance:
-3.15%
6M Performance:
+85.31%
1Y Performance:
-2.50%
1D Range:
Value
$16.41
$17.55
52W Range:
Value
$8.9201
$24.50

Biolife Solutions Inc Stock (BLFS) Company Profile

Name
Name
Biolife Solutions Inc
Name
Phone
425-402-1400
Name
Address
3303 Monte Villa Parkway, Suite 310, Bothell, WA
Name
Employee
40
Name
Twitter
@biolifesol
Name
Next Earnings Date
2024-05-08
Name
Latest SEC Filings
Name
BLFS's Discussions on Twitter

Biolife Solutions Inc Stock (BLFS) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-11-23 Initiated Craig Hallum Buy
Apr-25-22 Upgrade Oppenheimer Perform → Outperform
Oct-19-21 Initiated B. Riley Securities Buy
Oct-15-21 Resumed Cowen Outperform
May-14-21 Downgrade The Benchmark Company Buy → Hold
Mar-23-21 Upgrade The Benchmark Company Hold → Buy
Nov-10-20 Initiated KeyBanc Capital Markets Overweight
Sep-22-20 Downgrade Oppenheimer Outperform → Perform
Sep-18-20 Initiated Cowen Outperform
Aug-11-20 Downgrade The Benchmark Company Buy → Hold
Jul-08-20 Reiterated Maxim Group Buy
Feb-24-20 Initiated Lake Street Buy
Feb-19-20 Initiated The Benchmark Company Buy
Feb-06-20 Resumed B. Riley FBR Buy
Jan-08-20 Initiated Stephens Overweight
Nov-21-19 Initiated Oppenheimer Outperform
Jul-22-19 Initiated H.C. Wainwright Buy
Nov-10-17 Reiterated Maxim Group Buy
Sep-19-17 Reiterated Maxim Group Buy
Jul-05-17 Upgrade Janney Neutral → Buy
Mar-10-17 Reiterated Maxim Group Buy
Jan-19-17 Initiated Maxim Group Buy
View All

Biolife Solutions Inc Stock (BLFS) Financials Data

Biolife Solutions Inc (BLFS) Revenue 2024

BLFS reported a revenue (TTM) of $143.27 million for the quarter ending December 31, 2023, a -11.43% decline year-over-year.
loading

Biolife Solutions Inc (BLFS) Net Income 2024

BLFS net income (TTM) was -$66.43 million for the quarter ending December 31, 2023, a +52.49% increase year-over-year.
loading

Biolife Solutions Inc (BLFS) Cash Flow 2024

BLFS recorded a free cash flow (TTM) of -$18.88 million for the quarter ending December 31, 2023, a -0.03% decrease year-over-year.
loading

Biolife Solutions Inc (BLFS) Earnings per Share 2024

BLFS earnings per share (TTM) was -$1.52 for the quarter ending December 31, 2023, a +53.80% growth year-over-year.
loading
BioLife Solutions, Inc. develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death. The company offers HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications; and CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 for cryopreservation of stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services; and contract aseptic manufacturing formulation, filling, and finishing services for liquid media products. It markets its products to the regenerative medicine, bio-banking, and drug discovery markets, including hospital-based stem cell transplant centers, pharmaceutical companies, cord blood and adult stem cell banks, and hair transplant centers, as well as suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. The company markets and sells its products directly using its sales force, as well as through biolifesolutions.com; and through various regional distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
medical_instruments_supplies ATR
$143.33
price up icon 2.25%
medical_instruments_supplies TFX
$206.71
price up icon 0.00%
medical_instruments_supplies COO
$88.84
price down icon 1.21%
$75.98
price up icon 0.36%
medical_instruments_supplies BAX
$40.13
price down icon 0.25%
medical_instruments_supplies WST
$360.43
price down icon 2.10%
Cap:     |  Volume (24h):